Week 96 analyses of emergent drug resistance from the STaR Study: rilpivirine/emtricitabine/ tenofovir DF vs. efavirenz/emtricitabine/tenofovir DF single-tablet regimens

• Published in: Antiviral therapy Vol. 19; p. A123
• Main Authors: Porter, D P, Kulkarni, R, Fralich, T, Miller, M D, White, K L
• Format: Journal Article
• Language: English
• Published: 01.01.2014
• Subjects: Human immunodeficiency virus 1
• ISSN: 1359-6535

STaR (GS-US-264-0110) is a 96-week Phase 3b study evaluating the safety and efficacy of two single-tablet regimens, rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) in treatment-naive HIV-1-infected subjects with no restriction on viral load...